The Next Generation Migraine Therapies (NGMT) initiative is a comprehensive program designed to provide a multi-faceted approach to migraine education offered at no cost to healthcare providers. Brought to you by the American Headache Society, the program covers diagnosis and treatment of migraine and updates on the latest science.
In December 2020, the NGMT program will launch virtually on the AHS Education On Demand platform! The virtual program will center around pre-recorded lectures on new acute migraine treatments and new migraine prevention; behavioral approaches in migraine; and migraine diagnosis, epidemiology, and pathophysiology.
Live Q&A
NGMT registrants will also have access to live Q&A sessions with migraine experts for additional CME. Please visit the Education On Demand platform once registered to sign up for an upcoming Q&A.
WHO SHOULD ATTEND
This program is designed for neurologists, family practitioners, internists and other health professionals who would like more information on the proper diagnosis and treatment of chronic migraine patients.
PURPOSE/OBJECTIVE
At the conclusion of this activity, attendees should be better able to:
- Recognize the distribution of migraine and unmet needs on current treatments
- Discuss insights from basic science that underlie the next generation of migraine therapeutics
- Utilize calcitonin gene-related peptide (CGRP)-targeted therapies in migraine prevention
- Individualize and optimize migraine treatment using current and emerging therapeutic options
ACCREDITATION STATEMENT
The American Headache Society® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
The American Headache Society® designates this Other activity (recorded videos and live session) for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
INSTRUCTIONS FOR CLAIMING CME
- Attend sessions for which credit is sought in full (this includes watching on-demand courses).
- Complete the post-activity evaluation.
- A certificate of completion will be available once the evaluation is submitted.
FINANCIAL DISCLOSURES
The planners and faculty for this activity did not have any relationships to disclose unless listed here. All relevant relationships were mitigated prior to the start of the activity according to ACCME Standards.
DISCLOSURE OF COMMERICAL SUPPORT
The American Headache Society® received funding to support this activity from the following organizations:
Allergan, an AbbVie company
Eli Lilly and Company
Next Generation Migraine Therapies will launch virtually via the AHS Education On Demand platform.
| Pre-recorded Lectures Available On Demand |
| Introduction and Program Overview Kathleen B. Digre, MD, FAHS |
| Migraine Diagnosis, Epidemiology, and Pathophysiology Kathleen B. Digre, MD, FAHS |
| What’s New in Acute Migraine Treatment Stewart J. Tepper, MD, FAHS |
| Behavioral Approaches in Migraine Management Dawn C. Buse, PhD, FAHS |
| What’s New in Migraine Prevention Michael Marmura, MD, FAHS |
|
Live Q&A* *Separate registration required. Please register for the virtual program here, watch the on demand content, and then register separately for a live Q&A date that works for you via the Education On Demand platform. |
| Wednesday, June 23, 2021
5:00pm PDT/8:00pm EDT Presenters: |
Online registration is now open. To register at no cost, click here.
Once registered, please visit the Education On Demand platform to watch pre-recorded sessions and sign up for an upcoming Q&A*.
*Please note the registration system is not linked to the Education On Demand platform and may take up to a week for your registration to be added. If you are unable to access the meeting after that time, please email us at ahshq@talley.com or call 856-423-0043.
AHS gratefully acknowledges the educational grant support of the Next Generation Migraine Therapies Program from our industry supporters:
Allergan, an AbbVie company (NYSE: ABBV)
Eli Lilly and Company